MAB Discovery

Executive Summary

MAB Discovery GmbH is a German biotechnology company specializing in the discovery of high-quality functional monoclonal antibodies for therapeutic applications in oncology, immunology, and inflammatory diseases. Founded in 2010 by Dr. Stephan Fischer, the company leverages a unique discovery process to generate lead candidates for its pharma partners. As of 2023, eight of its programs have advanced to clinical trials, underscoring its ability to translate preclinical research into clinical-stage assets. The company operates as a private entity based in Munich, Germany, and continues to build its pipeline through proprietary antibody engineering and strategic collaborations. With a focus on addressing unmet medical needs in key disease areas, MAB Discovery positions itself as a valuable partner for pharmaceutical companies seeking novel antibody-based therapies.

Upcoming Catalysts (preview)

• TBDNew Pharma Partnership Announcement70% success
• TBDClinical Data Readout from Partner Programs50% success
• TBDSeries B or Later Financing Round60% success